G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. It offers COSELA, a product that helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer. The company also develops trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor for patients with first-line colorectal cancer and neoadjuvant breast cancer. G1 Therapeutics also offers rintodestrant, an oral selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER+) breast cancer.